Astrazeneca (AZN.US) combination therapy Truqap phase 3 trial results are positive.

Astrazeneca (AZN.US) announced today the positive results of the CAPItello-281 Phase 3 clinical trial.

Zhitong Finance01:10 ET

Astrazeneca's Capivasertib for prostate cancer has successfully completed Phase III trials, and the outlook for Kairui Pharmaceutical-B (2105.HK) AKT inhibitors is bullish.

On November 25th, AstraZeneca announced the success of its AKT inhibitor Capivasertib in the phase III CAPItello-281 study for the treatment of newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC). Following the approval and launch of Capivasertib for breast cancer indications, this study further confirmed the clinical value of AKT inhibitors. AKT inhibitors, as drugs that have shown potential in multiple cancers such as breast cancer, prostate cancer, and ovarian cancer, have a very broad market outlook. In recent years, an increasing number of pharmaceutical companies have begun to pay attention to AKT inhibitors.

Gelonghui Finance00:04 ET

AstraZeneca Reports Positive Phase 3 Results for Truqap in Prostate Cancer

Seeking Alpha17:55 ET

AstraZeneca (AZN) Receives a Buy From Goldman Sachs

TipRanksNov 25 07:55 ET · Ratings

TRUQAP (Capivasertib) Combination in PTEN-deficient Metastatic Hormone-sensitive Prostate Cancer Demonstrated Statistically Significant and Clinically Meaningful Improvement in Radiographic Progression-free Survival in CAPItello-281 Phase III Trial

BusinesswireNov 25 07:00 ET

AstraZeneca's Truqap Combo Demonstrated Statistically Significant Improvement

TipRanksNov 25 06:15 ET